Herein, we hypothesized that ovarian cancer patients with wild-type BRCA1/2 but with miRNA deregulation may also have better prognosis than patients with wild-type BRCA1/2 but no deregulation of miRNA. The gene discussed is BRCA1; the disease is ovarian cancer.